Browse Articles

Discover research articles across all indexed journals

S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: From the PRIAS-JAPAN study.

Journal of Clinical Oncology Takuma Kato, Tohru Yoneyama, Shingo Hatakeyama et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.358

358 Background: Recently, α2,3-sialylated prostate-specific antigen (S2,3PSA)% has been developed as a new serum biomarker for Prostate cancer (PCa). So, we aimed to investigate S2,3 PSA% to predict reclassification of the first repeat protocol biopsy (1st re-PBx) on Active surveillance (AS) for PCa patients. Methods: Patients who participated in PRIAS-JAPAN and its ancillary studies from August 2013 to January 2022 and met the following criteria were included: clinical stage: T1c/T2, PSA: <10ng/ml, PSA density: <0.2ng/ml/cc, number of positive cores: <2, Gleason score: <6. All participants were required to receive a blood sampling test on a protocol visit at inclusion and at the 1st re-PBx. Significant predictors of reclassification in 1st re-PBx were investigated in univariate and multivariate analyses by logistic regression analysis. Then, to assess the predictive power and thresholds for reclassification, we plotted Receiver Operating Characteristic (ROC) curves. Further, a decision curve analysis (DCA) was conducted to identify net benefits. Results: A total of 188 patients were analyzed. Reclassification was shown in 61 patients (32.4%). Both univariate and multivariate analysis by logistic regression analysis showed that S2,3PSA% at diagnosis and before 1st re-biopsy were both significant predictors of reclassification. In ROC analysis, S2,3 PSA% at diagnosis and before 1st re-biopsy had comparable predictive power. The AUC for S2,3PSA% before 1st re-biopsy was 0.63, with a sensitivity of 0.41 and specificity of 0.87. Analysis of the net benefit of PSA doubling time (PSADT) and S2,3PSA% with DCA using PSA, prostate volume, and age as the base model showed that S2,3PSA% had a higher net benefit than PSADT. Conclusions: S2,3PSA% before 1st re-PBx has a high net benefit for reclassification and is a useful tool for clinical decision making. Result of ROC curve analysis and decision curve analysis about S2,3PSA% for reclassification at 1st repeat biopsy. ROC curves about reclassification for differences in S2,3PSA% between baseline and before the 1st repeat PBx Variable AUC Standard Error p value (for AUC) 95% CI Optimal cut off point Sensitivity Specificity p value (vs baseline) S2,3PSA%(baseline) 0.65 0.05 <0.001 0.56 - 0.74 44.3 54.1% 75.6% - S2,3PSA%(before 1yr PBx) 0.63 0.05 0.0065 0.54 - 0.72 1.64 41.0% 87.4% 0.33 Decision curve analysis for reclassification at 1st repeat biopsy High Risk Threshold 0 0.1 0.2 0.3 0.4 0.5 Baseline model* 1 0.769 0.488 0.222 0.044 -0.016 Baseline model+PSADT** 1 0.77 0.492 0.29 0.011 -0.016 Baseline model+S2, 3PSA%** 1 0.769 0.504 0.215 0.186 0.131 *Baseline model is composed of age, prostate volume and PSA before 1yr PBx. **The value of PSADT and S2,3PSA% are calculated by the data before 1yr PBx.

Research on the construction of a sustainable scientific research capability evaluation model for university teachers based on the T-S fuzzy neural network

PLoS ONE Jia Wen, Pinhong Zeng Feb 10, 2025 DOI: 10.1371/journal.pone.0313608

Introduction This study aims to enhance educational quality and academic standards by proposing a model based on critical research ability indicators to objectively evaluate the sustainable scientific research capabilities of university teachers. Methods Using T-S fuzzy neural network technology, we developed an evaluation model to measure the sustainability of university teachers’ research capabilities. We collected data from 126 university teachers, using 90 samples for training and 36 for testing, to ascertain the model’s applicability and accuracy. Results The T-S fuzzy neural network showcased exceptional learning efficiency and achieved a 98.15% accuracy rate in assessing the sustainable scientific research capabilities of university teachers, outperforming both Naive Bayes and BP neural networks in effectiveness. Conclusion The research successfully constructs a T-S fuzzy neural network-based evaluation model for assessing the sustainable scientific research capabilities of university teachers. With high accuracy and broad applicability, this model is an effective tool for objectively evaluating university teachers’ research capabilities, clearly achieving the study’s objective.

Phenotypic and genotypic characterization of Candida parapsilosis complex isolates from a Lebanese hospital

Scientific Reports Reine El Hady, Nour Fattouh, Marc Finianos et al. Feb 10, 2025 DOI: 10.1038/s41598-024-84535-5

Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.

Journal of Clinical Oncology Guillermo de Velasco, Laurence Albiges, Thomas Powles et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.538

538 Background: At first interim analysis of the randomized, multicenter, open-label, phase 3 LITESPARK-005 study (NCT04195750), belzutifan was associated with a significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) vs everolimus in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) after both anti–PD-(L)1 and VEGF-targeted therapy. PFS and ORR results remained consistent at final analysis (FA); significant improvement in overall survival (OS) in this heavily pretreated population was not observed. Efficacy outcomes by baseline disease characteristics and tumor burden at FA are presented here. Methods: Pts were aged ≥18 years, had advanced ccRCC, and 1–3 prior systemic regimens (including ≥1 prior PD-[L]1 inhibitor and VEGFR-TKI in combination or in sequence). Belzutifan 120 mg QD or everolimus 10 mg QD were administered to randomized (1:1) pts until disease progression or unacceptable toxicity. An exploratory analysis of PFS and ORR per RECIST 1.1 by central review and OS was conducted in subgroups by bone metastasis (present at baseline, yes vs no), liver metastasis (present at baseline, yes vs no), and baseline tumor burden (sum of diameters of target lesions, < median vs ≥ median). No formal statistical testing was performed. Results: A total of 374 pts were randomized to belzutifan, and 372 to everolimus. At FA (data cutoff: April 15, 2024), median follow-up was 35.8 mo (range 26.9–49.2) for the total population. PFS and ORR benefits with belzutifan vs everolimus were generally consistent with the total population across all analyzed subgroups (Table). In line with the total population at FA, improvement in OS was not observed across most subgroups. Conclusions: Belzutifan is a novel treatment option for patients with advanced ccRCC after prior anti–PD-(L)1 and VEGF-targeted therapies. Exploratory analysis suggests that PFS and ORR benefits with belzutifan vs everolimus are generally consistent across subgroups by baseline disease characteristics and tumor burden. Clinical trial information: NCT04195750 . Bone mets, yes Bone mets, no Liver mets, yes Liver mets, no Sum target lesion diameters,< median Sum target lesion diameters,≥ median Bel Eve Bel Eve Bel Eve Bel Eve Bel Eve Bel Eve N 187 181 187 191 89 103 285 269 174 193 198 171 PFS, median, mo 3.7 4.3 7.0 6.3 4.6 3.7 5.6 5.8 7.3 5.7 4.2 4.8 PFS HR(95% CI) 0.88(0.69–1.11) 0.65(0.51–0.82) 0.55(0.39–0.77) 0.84(0.69–1.02) 0.67(0.52–0.86) 0.80(0.63–1.01) OS, median, mo 15.0 15.1 26.5 23.7 19.1 12.9 21.7 21.8 26.4 26.5 17.3 12.3 OS HR(95% CI) 0.95(0.75–1.20) 0.89(0.69–1.15) 0.63(0.45–0.88) 1.06(0.86–1.30) 0.95(0.73–1.24) 0.76(0.61–0.96) ORR, % 17.6 2.8 27.8 4.2 24.7 3.9 22.1 3.3 28.7 4.1 17.7 2.9 Bel=belzutifan; eve=everolimus; mets=metastasis.

Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS.

Journal of Clinical Oncology Joan Carles, Bertrand F. Tombal, Maha H. A. Hussain et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.143

143 Background: In ARASENS, darolutamide (DARO) + ADT + docetaxel (DOC) significantly reduced the risk of death by 32.5% (HR 0.68; 95% CI 0.57–0.80; P <0.0001) vs placebo (PBO) + ADT + DOC with similar incidence of treatment-emergent adverse events (TEAEs) between groups in patients (pts) with mHSPC. DARO + ADT + DOC has become one of the standards of care in mHSPC. We report post-hoc efficacy and safety in pts by age subgroups (<75 y, ≥75 y) in ARASENS. Methods: Pts were randomized to receive DARO 600 mg orally twice daily or PBO, with ADT + DOC. Age subgroups were analyzed for baseline characteristics including ongoing comorbidities, treatment duration, completion of DOC therapy, use of first subsequent therapy, key efficacy outcomes, and safety. Results: Of 1305 pts analyzed in ARASENS, ages ranged from 41–89 y, with 1086 pts <75 y (83%; DARO n=546; PBO, n=540) and 219 pts ≥75 y (17%; DARO n=105; PBO n=114). Baseline characteristics were generally similar in the DARO and PBO groups by age subgroup. The most common comorbidities by system organ class in pts <75 y and ≥75 y were vascular (55%, 67%), musculoskeletal/connective tissue (42%, 42%), and metabolism/nutrition (35%, 43%) disorders. Treatment duration was consistently longer with DARO vs PBO (<75 y: 41.2 vs 16.8 mo; ≥75 y: 38.5 vs 15.0 mo). Most patients completed 6 cycles of DOC (<75 y: 89%, 88%; ≥75 y: 80%, 76%). Among pts who entered follow-up, fewer DARO vs PBO pts initiated subsequent therapy independent of age (<75 y: 57% vs 76%; ≥75 y: 54% vs 73%). The overall survival (OS) benefit of DARO vs PBO was consistent across age subgroups (<75 y: HR 0.70, 95% CI 0.58–0.84; ≥75 y: HR 0.61, 95% CI 0.41–0.91). Time to metastatic castration-resistant prostate cancer (mCRPC) was longer with DARO vs PBO across age subgroups (<75 y: HR 0.35, 95% CI 0.30–0.43; ≥75 y: HR 0.42, 95% CI 0.28–0.64) as was time to initiation of subsequent therapy (<75 y: HR 0.40, 95% CI 0.34–0.48; ≥75 y: HR 0.35, 95% CI 0.22–0.54). TEAEs were generally similar between DARO and PBO, with slightly higher incidence rates in older pts. Few patients discontinued DARO or PBO due to TEAEs in both age subgroups (<75 y: 13.2%, 9.1%; ≥75 y: 15.1%, 17.7%). The most common grade 3/4 TEAEs were generally similar between DARO and PBO across age subgroups and occurred most frequently during overlapping DOC treatment. TEAEs commonly associated with androgen receptor pathway inhibitors occurred at similar incidences between treatment groups in both age subgroups. Conclusions: Pts with mHSPC benefited from DARO + ADT + DOC irrespective of age (<75 y and ≥75 y), with consistent improvements in OS, time to mCRPC, and time to initiation of subsequent therapy. DARO was well tolerated in both age subgroups, with similar incidences of TEAEs vs PBO. Clinical trial information: NCT02799602 .

Changes in circulating tumor cells (CTCs) and HER2 expression in evaluating the efficacy of neoadjuvant disitamab vedotin plus toripalimab treatment in patients with muscle-invasive bladder cancer (MIBC).

Journal of Clinical Oncology Yudong Cao, Ruojing Li, Shuo Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.837

837 Background: Disitamab vedotin (DV) combined with toripalimab has shown promising efficacy as neoadjuvant therapy for MIBC, with a pathological CR (pCR) rate of 62.1% in the previous report (2024 ASCO). In real-world practice, many patients who achieved clinical complete response (cCR) after neoadjuvant therapy, confirmed by re-TURBT, imaging, and urine cytology, opted for bladder-preserving treatment (BPT). However, biomarkers to confirm the absence of residual tumors in cCR pts are lacking. This study aims to evaluate the correlation between changes in CTCs and HER2+ CTCs during neoadjuvant therapy with clinical efficacy outcomes in MIBC. Methods: 18 pts were retrospectively included from July 2023 to July 2024. The primary endpoint was to assess the correlation between changes in CTCs and HER2+ CTCs before and after neoadjuvant therapy, and clinical efficacy (cCR or non-cCR). Eligible pts had previously untreated MIBC (cT2-T3N0-1M0) with HER2 expression of IHC ≥ 2+. Pts received DV (2 mg/kg) plus toripalimab (3 mg/kg) every two weeks for six cycles, followed by radical surgery or BPT for cCR pts (choice made after communication between the physician and the pts). cCR criteria included no residual tumor confirmed by re-TURBT, no evidence of tumor on imaging, and negative urine cytology. Peripheral blood samples were collected to measure CTC counts and HER2 phenotype by HER2-iFISH. Results: Among 18 pts, 15 (83.3%) achieved cCR, while 3 pts (16.7%) were in the non-cCR group, including 2 pts with cPR confirmed as pT2N0 postoperatively, and 1 pt with clinical progression (cPD). All 15 cCR pts underwent BPT. There were no significant differences in the total CTCs and HER2+ CTCs between the cCR and non-cCR groups before treatment (P = 0.426, P = 0.654, respectively). After neoadjuvant therapy, CTC and HER2+ CTC counts were significant lower in the cCR group compared to the non-cCR group (P = 0.039, P = 0.005, respectively). Only 1 (6.7%) cCR pt had detectable HER2+ CTCs post-treatment, while all 3 non-cCR pts had measurable HER2+ CTCs. Conclusions: Changes in CTCs and HER2+ CTCs correlated with clinical efficacy outcomes of DV plus toripalimab neoadjuvant therapy, particularly in HER2+ CTCs. CTCs and CTC HER2 expression may serve as potential biomarkers for evaluating clinical efficacy and guiding treatment strategies in MIBC. The clinicopathological characteristics of the 18 MIBC patients. Characteristic All patients (n=18) cCR (n=15) non-cCR (n=3) P value Clinical T stage, n (%) 1.00 cT2 10 (55.6) 8 (53.3) 2 (67) cT3 8 (44.4) 7 (46.7) 1 (33) Clinical N stage, n (%) 1.00 cN0 15 (83.3) 12 (80.0) 3 (100) cN1 3 (16.7) 3 (20.0) 0 (0) HER-2 expression, n (%) 0.44 2+ 15 (83.3) 13 (86.7) 2 (66.7) 3+ 3 (16.7) 2 (13.3) 1 (33.3)

Treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 35 real-world observational studies.

Journal of Clinical Oncology Amit D Raval, Viji Queen V, Matthew J. Korn et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.101

101 Background: Treatment landscapes have changed dramatically in prostate cancer in the past decade. Therapies like androgen receptor pathways inhibitors (ARPIs), which were initially approved for mCRPC are now approved in the earlier disease spectrum, including biochemical recurrence (BCR), non-metastatic castration-resistant prostate cancer (nmCRPC), and hormone-sensitive metastatic prostate cancer (mHSPC). Further, several other life-prolonging therapies, including radiopharmaceuticals, immunotherapies, and poly-ADP ribose polymerase inhibitors (PARPi), have been approved for mCRPC in the last decade. Given these changes, this systematic literature review (SLR) aimed to summarize treatment patterns and survival in patients with mCRPC. Methods: Electronic databases (PubMed, Embase) and key conferences (2022-2024) were searched systemically for real-world (RW) observational studies published between Jan 2015 and March 2024 that examined treatment patterns and survival in patients with mCRPC. A GenAI-powered literature review platform assisted in study selection alongside human validation, and independent reviewers extracted and assessed the data for narrative synthesis of key findings. Results: From 4,565 retrieved citations, 35 studies with a total of 86,131 patients with mCRPC met inclusion criteria. In most studies, patient median age ranged from 65 to 75. Studies predominantly utilized electronic medical records (EMR)/chart review (n=24), followed by a registry/-linked claims (n=10). Most studies were from North America (n=21; 18 United States; 3 Canada), followed by Europe (n=6), Asia (n=3), Oceania (n=3), and others (n=2). Bone and visceral metastases were present in ≥ 70% of mCRPC and ≤30% in most studies, respectively. ARPI was the most frequently utilized first line of therapy(1L) for mCRPC in all studies (≥50% in most studies), followed by chemotherapy, albeit with varying magnitude by geographic regions. Chemotherapy for 1L mCRPC was more common in Europe and Oceania than in the US. The use of radiopharmaceuticals, PARPIs, and immunotherapy was low in most studies (<10%) as 1L mCRPC. Most studies found ARPI to ARPI was the most common 1L to 2L mCRPC sequence, though in few studies, ARPI-chemotherapy was the common 1L to 2L mCRPC sequence. In most studies, median real-world overall survival ranged from 18 to 27 months and varied by genetic mutation status. Conclusions: Findings highlight that ARPI remained the most utilized 1L/2L in men with mCRPC, and back-to-back ARPI was also a common practice even after the availability of the other life-prolonging therapies. This SLR highlights the need to optimize treatment beyond systemic hormone therapy.

Gains vs losses in pay-for-performance: Stated preference evidence from a U.S. survey

PLoS ONE Justin G. Trogdon, Aveena Khanderia, Kathryn Brignole et al. Feb 10, 2025 DOI: 10.1371/journal.pone.0318704

Background Pay-for-performance (P4P) incentives can be paid as a bonus (gain) or a penalty (loss). Diminishing marginal utility of wealth suggests that, starting from the same initial wealth, individuals dislike losses more than they like equivalent gains. Objective This study reports the minimum financial gain or loss required to motivate primary care providers and clinical staff to try to increase their human papillomavirus (HPV) vaccination rates. Data In 2022, we conducted a national U.S. survey through WebMD’s Medscape Network of clinical staff working in primary care clinics that provided HPV vaccination to children ages 9 through 12 years (N = 2,527; response rate = 57%). Methods We randomized respondents to one of two hypothetical HPV vaccine incentive designs: a bonus for reaching an unspecified target HPV vaccination rate and a penalty for failing to reach the unspecified target. The primary outcome is the self-reported smallest incentive amount (U.S. dollars) that would motivate participants to try and increase their HPV vaccination rates. We tested for differences across P4P designs using unadjusted responses and linear regressions adjusting for clinic and respondent characteristics. We also tested for heterogeneous responses by experience with incentizves, training, and rurality. Results The mean amount required to motivate effort was $2,155 in the gain P4P design and $1,185 in the loss P4P design (unadjusted difference =  $970 [p < 0.001], adjusted difference =  $967 [p < 0.001]). There were no heterogeneous effects by rurality or experience with incentives. Physicians reported the highest differences (in dollars) between gain and loss P4P designs. Conclusions Stated preference data from primary care clinical staff suggests that effective P4P incentives could be half as large if designed as losses rather than gains.

Unraveling a novel therapeutic facet of Etravirine to confront Hepatocellular Carcinoma via disruption of cell cycle

Scientific Reports Gouri Nair, G. R. Saraswathy, Jesil Mathew Aranjani et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87676-3

Abstract Hepatocellular Carcinoma (HCC) is a malignancy with high mortality rates and limited treatment options. This study aimed to unearth the repurposable potential of FDA-approved drugs against specific genetic targets governing the HCC pathological pathways. The transcriptomics microarray datasets were explored to retrieve the HCC specific differentially expressed genes, and the significant genes were fed in Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database to capture the protein-protein interactions, which were visualized in Cytoscape. This revealed CCNA2, a cell cycle regulator, as a potential target, which mediates its action by interacting with CDK1 and CDK2. Further, with the intention of identifying inhibitors for CDK1 and CDK2, a drug library was created, and the drugs were virtually screened against their respective targets via molecular docking and dynamics studies. This captured the binding affinity of Steviolbioside towards CDK1 and Etravirine and Fludarabine towards CDK2. In vitro, validation confirmed the cytotoxic potential of Etravirine and Fludarabine in Huh-7 cell lines. Further, enzymatic assays, gene expression analysis, and cell cycle analysis signified the anti-proliferative potential of Etravirine in Huh-7 cells via inhibition of CDK2. In this drug repurposing venture, Etravirine, a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of HIV, emerged as a promising candidate for HCC treatment. The findings warrant further preclinical and clinical investigations to ascertain the repurposable potential of Etravirine against HCC, particularly in patients with viral infections.

Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle invasive urothelial bladder cancer (HOPE-02).

Journal of Clinical Oncology Feng Wen, Tianhai Lin, Ping Tan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.786

786 Background: The “bladder-sparing” trimodal therapy (TMT) has gained popularity among selected patients with muscle-invasive bladder cancer (MIBC) who are either unfit for or decline radical cystectomy (RC). This Phase 2 study aimed to evaluate the bladder-sparing efficacy of neoadjuvant chemotherapy combined with tislelizumab, followed by radiotherapy for high-risk, locally advanced MIBC, who were considered as non-ideal candidates for bladder-sparing treatment (Trial registration number: ChiCTR2100045213). Methods: Patients diagnosed with cT2-4bN0-3M0-1a MIBC will be included in the study if they demonstrate non-progression of disease (PD) after two cycles of neoadjuvant chemotherapy (gemcitabine and cisplatin or carboplatin) combined with tislelizumab. Radiotherapy will be administered to patients after one or two additional cycles of neoadjuvant therapy, and tislelizumab will continue for up to one year. The primary endpoint is the complete response rate (CR, including T0/Ta/Tis) after radiotherapy, while the secondary endpoints include progression-free survival (PFS), bladder-intact disease-free survival (BI-DFS), overall survival (OS), and toxicity. Results: Preliminary results of safety were presented at the ASCO-GU meeting in 2023, and we are now reporting the long-term outcomes. A total of 45 patients were enrolled. The median follow-up time was 36.10 ± 2.92 months. All participants completed 3 to 4 cycles of neoadjuvant therapy, resulting in a CR rate of 51.11%. Among the patients, 36 completed radiotherapy and underwent efficacy evaluations through imaging and cystoscopic biopsy. However, nine patients withdrew from the study due to personal requests for surgery, traditional Chinese medicine, or changes in systemic therapy. Of the 36 patients, 2 were Tis, and 31 were T0 after radiotherapy, indicating a primary CR rate of 100%. The 2 Tis patients received intravesical BCG vaccine therapy and achieved T0 by the time of the second therapeutic evaluation. No patient underwent radical cystectomy. 3-year PFS rate and 3-year BI-DFS were 76.0%, and 3-year OS was 81.0%. One patient experienced bladder recurrence with T1, while 3 patients developed distant metastases. Four patients died, with 2 deaths attributed to other reasons. Conclusions: Neoadjuvant chemotherapy combined with tislelizumab provides an opportunity for suboptimal candidates to become suitable for bladder-sparing approaches, and radiotherapy-based bladder-preserving treatment demonstrated excellent long-term efficacy and acceptable toxicity, making it a potentially optimal strategy for high-risk, locally advanced MIBC patients who wish to preserve their bladder. Clinical trial information: ChiCTR2100045213.

Phase 3 OMAHA-004 study of CYP11A1 inhibitor opevesostat versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after 1 prior NHA.

Journal of Clinical Oncology Christian Gratzke, Donald Charles Vile, Zheng Hong Chen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps301

TPS301 Background: Androgen receptor (AR) somatic mutation activation is a resistance mechanism to AR-directed therapies (ADT) in mCRPC. Upstream targeting of androgen biosynthesis may provide a therapeutic advantage over available AR-directed therapies in patients with mCRPC. Opevesostat (MK-5684; ODM-208) is an oral, nonsteroidal inhibitor of cytochrome P450 11A1 (CYP11A1), a catalyst of the first and rate-limiting step of steroid biosynthesis. By blocking the first step of the enzymatic pathway, opevesostat has the potential to inhibit all steroid hormones involved in AR signaling activation. In the phase 1/2 CYPIDES study, opevesostat had antitumor activity in patients with heavily pretreated mCRPC, especially in those with AR ligand binding domain (AR-LBD) mutations (1). The randomized, open-label, phase 3 OMAHA-004 trial (NCT06136650) will evaluate the efficacy and safety of opevesostat versus abiraterone or enzalutamide in patients with molecularly unselected mCRPC previously treated with 1 prior NHA. Methods: Eligible patients have mCRPC that progressed during ADT ≤6 months before screening and during/after 1 NHA for hormone-sensitive prostate cancer or non-mCRPC. Approximately 1500 patients (375 with, 1125 without AR-LBD mutations) will be randomly assigned 1:1 to receive opevesostat 5 mg PO BID (+ dexamethasone 1.5 mg and fludrocortisone 0.1 mg PO QD) or abiraterone acetate 1000 mg PO QD (if prior enzalutamide/darolutamide/apalutamide) or enzalutamide 160 mg PO QD (if prior abiraterone). Primary endpoints are radiographic progression-free survival per Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1 by blinded independent central review (BICR) and overall survival in AR-LBD mutation–positive and –negative disease, separately. Secondary endpoints include time to initiation of first subsequent anticancer therapy or death; objective response rate and duration of response per PCWG3-modified RECIST v1.1 by BICR; and safety. Recruitment is ongoing. 1. Fizazi et al. NEJM Evid. 2024. Clinical trial information: NCT06136650 .

PSA response and survival based on metastatic site in patients with metastatic castration resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).

Journal of Clinical Oncology Joseph David Allen, Colin P Bergstrom, Hong Song et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.107

107 Background: Patients (pts) with mCRPC can have different metastatic sites with variable outcomes. Lu177-PVT is a novel treatment for mCRPC but response and outcomes in the real world are still being defined. We hypothesized that pts with lung and liver metastases (mets) would have worse outcomes (lower PSA response and shorter survival) with Lu177-PVT than those without as advanced of disease spread. Methods: This retrospective cohort study analyzed pts with mCRPC who were treated with at least one dose of Lu177-PVT. PSA50, PSA90, and overall survival were assessed for three comparisons of pts: bone only vs. other mets (including other site ± bone), lung-involved vs. lung-absent, and liver-involved vs. liver-absent. PSA50 and PSA90 were defined as achieving any reduction in PSA below 50% and 90% of baseline prior to Lu177-PVT therapy, respectively. Comparisons between groups were made using univariable logistic regression for PSA50 and PSA90 and Cox regression for OS. Results: We included 100 pts for OS analyses and 97 pts for PSA50 and PSA90 analyses treated between 03/2019 and 09/2024. Three pts were excluded from PSA analyses due to absence of baseline PSA prior to Lu177-PVT. Median age at Lu177-PVT start was 66 years, 67% white race, 45% ever smoker, median BMI was 26 kg/m 2 , 5 median previous lines of treatment, 77% received prior chemotherapy, and 4 median number of Lu-177-PVT treatments received. At time of initial Lu177-PVT, 94% had at least bone mets, 12% had LN mets, 14% had lung mets, 15% had liver mets, and 9% had other mets. Table shows results of all comparisons. Pts with only bone mets (vs those with other site ± bone) had numerically (not significant) longer OS (Table; median [m]OS 19 vs. 13 months, HR 0.88, p-value 0.70) and similar PSA50 and PSA90 rates. Pts with liver-involved (vs liver-absent) had a numerically shorter OS (mOS 15 vs. 18 months, HR 1.45 p-value 0.38) and lower (not significant) PSA90. Pts with lung-involved (vs lung-absent) had numerically shorter OS (15 vs. 18 months, HR 1.28, p-value 0.58) and lower PSA90. Conclusions: Pts with mCRPC responded to Lu177-PVT regardless of metastatic sites in our study, though liver mets had numerically lower OS. Study limited by small power and retrospective study design. Future work is needed to further dissect the interplay between Lu177-PVT response and metastatic disease sites. Results. N Median Lu177-PVT cycles received Median Overall Survival, months (95% CI) HR for OS, (95% CI) PSA50%, (95% CI) OR for PSA50, (95%CI) PSA90%, (95% CI) OR for PSA90, (95%CI) Bone only 56 5 19 (1-40) 0.88 (0.45-1.71) 58 (43-70) 1.04 (0.46-2.36) 33 (20-46) 1.56 (0.64-3.96) Lung-involved 15 4 15 (3-34) 1.28 (0.53-3.01) 57 (27-79) 0.97 (0.31-3.19) 14 (2-40) 0.37 (0.05-1.47) Liver-involved 15 3 15 (3-35) 1.45 (0.63-3.32) 67 (38-88) 1.57 (0.51-5.40) 13 (2-40) 0.33 (0.05-1.32)

A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).

Journal of Clinical Oncology Megan Crumbaker, Samantha Shekar, Mitchell G. Lawrence et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.218

218 Background: Bipolar androgen therapy (BAT) is a safe and well-tolerated treatment paradigm in metastatic castrate resistant prostate cancer (mCRPC) but response rates and duration are modest. Preclinical data suggests supraphysiologic androgens interrupt DNA relicensing and increase double-stranded DNA breaks, suggesting a potential synergy with the addition of carboplatin chemotherapy. We assessed the safety and efficacy of this treatment combination in Arm B of the HIGH-TeCH trial. Methods: Men with refractory mCRPC after at least one line of taxane based chemotherapy and androgen signaling inhibitor received four weekly testosterone enanthate (500mg IM) with Carboplatin (AUC 5) and androgen deprivation therapy. Five (24%) PSA50 responses were achieved at planned interim analysis of the first 21 patients, meeting threshold for study expansion to a total of 40 participants. Results: Currently, 37 of a target total 40 patients have been recruited. Median follow up was 14.8 months as of 1st October 2024. Median age 72. Median prior lines of treatment 3; 51% of patients had prior 177-Lutetium. 27 patients discontinued treatment for disease progression (PSA, radiological, clinical), 1 discontinued due to a serious adverse event (CVA) and 9 patients remain on trial. Median of 5 cycles of BAT with Carboplatin were administered. Seven (19%) patients had a PSA response ≥ 50%. Fourteen (38%) patients had clinical benefit (> 6 months duration on study). Median progression-free survival was 6.6 months (95% CI, 5.5 – 9.9). Median overall survival was 20.4 months (95% CI, 15.5 – not reached). Thirty-one (84%) patients experienced a treatment–related adverse event (TRAE); of which, 94% were grade 1 – 2. Highest rates of TRAEs were fatigue (52%), nausea (39%), musculoskeletal pain (23%), constipation (23%). There was no grade 4 TRAEs or deaths. Conclusions: BAT with carboplatin has an acceptable safety profile and demonstrated clinical benefit in heavily pre-treated mCRPC patients. Accrual will be completed imminently with final analysis to be presented. Translational studies to identify predictive biomarkers and quality of life analyses are underway. Clinical trial information: NCT00309985 .

3 kV fully vertical <i>β</i>-Ga2O3 junction termination extension Schottky barrier diode with sputtered p-GaN

Applied Physics Letters Qingyuan Chang, Bin Hou, Ling Yang et al. Feb 10, 2025 DOI: 10.1063/5.0243637

In this work, we present the fabrication of a fully vertical β-Ga2O3 Schottky barrier diode with junction termination extension (JTE-SBD) utilizing a p-GaN layer produced by sputtering, offering a solution to the absence of p-Ga2O3 materials. The p-GaN/n-Ga2O3 JTE-SBD demonstrates a turn-on voltage (Von) of 0.8 V, a specific on-resistance (Ron,sp) of 6.15 mΩ·cm2, an ideality factor (n) of 1.24, a breakdown voltage of 3 kV, and a Baliga's Figure of Merit of 1.46 GW/cm2. The current–voltage–temperature (I–V–T) testing has confirmed a transition in the dominant leakage mechanisms from the Poole–Frenkel mechanism to variable-range hopping.

Research on intelligent routing with VAE-GAN in the internet of body

PLoS ONE Song Qian, Tianping Zhang, Siping Hu Feb 10, 2025 DOI: 10.1371/journal.pone.0317698

The "Internet of Body" is an emerging technology that is centered on the human body and connected to the Internet. It can monitor a variety of human data (such as heart rate, blood oxygen content, etc.) and communicate with digital pills, wearable devices, etc. It has been widely used in the field of medical health. However, when other devices access the Internet of Body on a large scale, there will be load imbalance caused by the difficulty in selecting the optimal route, which will affect the overall throughput and may even fail to transmit and endanger life. The traditional artificial intelligence routing algorithm cannot deal with the low model prediction accuracy and poor generalization ability caused by large noise and small data volume. This paper proposes an artificial intelligence routing algorithm, combines the variational autoencoder (VAE) and the generative adversarial network model (GAN) to construct a VAE-GAN model to generate multiple sets of data to achieve data enhancement on the Internet of Body. The optimization goals are to maximize the throughput of the Internet of Body and minimize the transmission cost. The entire routing problem is expressed as a Markov decision and the optimal transmission path is solved by learning previous historical experience to generate the real-time optimal route. Experiments have shown that this scheme can achieve the optimal route according to the transmission capacity of the real-time path and only requires fewer computing resources. It achieves load balancing of the entire network and avoids network congestion. The average throughput is much higher than that of traditional routing, and the advantage is more obvious under high load.

A texture enhanced attention model for defect detection in thermal protection materials

Scientific Reports Jialin Song, Zhaoba Wang, Kailiang Xue et al. Feb 10, 2025 DOI: 10.1038/s41598-025-89376-4

Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1/2 MK-2870-001 study.

Journal of Clinical Oncology Dingwei Ye, Shusuan Jiang, Fang Yuan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.796

796 Background: Sacituzumab tirumotecan (sac-TMT; also known as MK-2870/SKB264) is a TROP2 targeting ADC with a hydrolytically cleavable linker and a topoisomerase I inhibitor payload, KL610023 (average drug-to-antibody ratio, 7.4). In patients (pts) with urothelial carcinoma (UC), treatment with the anti-TROP2 ADC sacituzumab govitecan led to treatment-related grade ≥3 neutropenia in 35% of pts and febrile neutropenia in 10%. Cohort 9 of the MK-2870-001 (KL264-01; NCT04152499) evaluated sac-TMT monotherapy in pts with unresectable, locally advanced/metastatic UC who progressed on or after prior anti-cancer treatments. Methods: Eligible pts were ≥18 y, had histologically or cytologically confirmed locally advanced/metastatic UC, and had experienced PD on ≥1 prior line of platinum-based therapy. Platinum ineligible pts were eligible if they received prior anti-PD-(L)1 therapy; prior neoadjuvant/adjuvant therapy was counted as a line of therapy if pts progressed ≤12 mo of last dose. Pts must have ECOG PS of ≤1 and measurable disease by CT/MRI. Pts received sac-TMT 5 mg/kg Q2W until PD, unacceptable toxicity, or withdrawal of consent. Primary objective was ORR per RECIST v1.1 by investigator. Secondary objectives included DOR, PFS, OS, and safety. Results: 49 pts were treated by data cutoff (Jun 30, 2024) with a minimum follow-up of ≥9 wk (11 pts received sac-TMT as a second-line treatment; 38 received sac-TMT as a third-line or later treatment). Median age was 62 and 61 y, respectively; most pts were Asian (81.8%; 100%). Median follow-up was 9.5 mo (range, 7.5–16.2) and 11.7 mo (range, 7.8–17.4), respectively. By data cutoff, 7 (63.6%) and 29 (76.3%) pts, respectively, had discontinued treatment mostly due to PD (45.5%; 55.3%). Treatment-related grade ≥3 AEs occurred in 29/49 (59.2%) of pts, the most common (≥20%) of which were anemia (38.8%) and decreased neutrophil count (28.6 %). No treatment-related deaths were reported by safety data cutoff (May 21, 2024). Efficacy outcomes are shown in the Table. Conclusions: sac-TMT monotherapy had promising antitumor activity in pts with advanced UC who progressed on 1L platinum-based therapy. Clinical trial information: NCT04152499 . Outcome UC 2Lsac-TMT 5 mg/kg (n=11) UC 3L+sac-TMT 5 mg/kg(n=38) Confirmed ORR a n (%) 5 (45.5) 10 (26.3) 95% CI 16.7–76.6 13.4–43.1 CR n (%) 1 (9.1) 0 PR n (%) 4 (36.4) 10 (26.3) SD n (%) 3 (27.3) 17 (44.7) PD n (%) 2 (18.2) 10 (26.3) Not evaluable n (%) 1 (9.1) 1 (2.6) Median DOR b , months (range) NE (3.48+ to 13.86+) NE (2.10 to 14.95+) Median PFS b , months (95% CI) 5.78 (1.68–NE) 5.03 (3.52–7.39) Median OS b , months (95% CI) NE (2.0–NE) 11.5 (8.9–NE) NE, not evaluable. “+” indicates no progressive disease or death as of last disease assessment. a Includes all pts as-treated, and percentages are based on number of pts in each subgroup. b Based on Kaplan-Meier method for censored data.

Real-world treatment patterns and survival in men with metastatic castration-resistant prostate cancer (mCRPC) who previously progressed from metastatic hormone-sensitive prostate cancer (mHSPC) between 2020 to 2023 in the United States.

Journal of Clinical Oncology Amit D Raval, Guifang Chen, Matthew J. Korn et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.99

99 Background: While androgen deprivation therapy (ADT) is a backbone for managing mHSPC, therapies initially approved for mCRPC, such as androgen receptor pathways inhibitors like abiraterone (ABI) and non-ABI ARPIs ( enzalutamide, apalutamide, darolutamide), and/or docetaxel, are now guideline-recommended for use in mHSPC. Evidence on how this shift in mHSPC management affects current mCRPC treatment patterns and survival is lacking. Methods: A retrospective cohort of men treated for mCRPC between 2020-2023 was identified in the ConcertAI NLP360 oncology electronic medical records (EMR) database in the United States. Men with mCRPC were identified based on their first record for castration resistance after an earlier diagnosis of mHSPC. Men were required to have continuous EMR activity ≥12 months pre-mCRPC (baseline) and ≥6 months post-mCRPC. Line of therapy was identified as ABI, non-ABI ARPI, taxane-based chemotherapy, poly (ADP-ribose) polymerase inhibitors (PARPIs), immunotherapy (pembrolizumab, sipuleucel-T), radiopharmaceuticals (Ra-223, 177 Lu-PSMA-RLT), alone or in combination. Results: The cohort comprised 609 men with mCRPC who had progressed from mHSPC. Median age was 72 years (interquartile range: 66-79). Nearly 85% had ECOG 0-1, 79% had bone metastases, and 42% received bone-health agents during baseline. Most men had received ADT alone for mHSPC (53%), followed by ADT+ABI (19%), ADT+non-ABI ARPI (18%), and ADT+Docetaxel (10%). Overall, the most common first line treatment (1L Tx) for mCRPC was ARPI (62%; enzalutamide [28%] and ABI [25%]) and chemotherapy (22%). This trend was consistent in men with prior ADT for mHSPC. Among those who had received ADT+ARPI for mHSPC, sequentially ARPI as 1L Tx was common (most common on ADT+ABI and 2 nd most common among ADT+non-ABI ARPI). 1L chemotherapy use was more common among men with ADT+ARPI/DOC for mHSPC, compared to ADT alone (see Table 1), though was still less than 50% in the ADT+non-ABI ARPI group. Median real-world overall survival from 1L Tx was 21 months (95% confidence interval: 18, 25). Conclusions: With more than half of patients having received ADT alone in mHSPC, use of ARPIs was the most common 1L Tx option in mCRPC. Back-to-back use of ARPI upon progression to mCRPC was common. These findings highlight the need to explore alternative treatment option in mCRPC beyond ARPIs to improve survival in men with mCRPC. 1L mCRPC treatment patterns by prior mHSPC therapy. 1L Therapy Overall Prior mHSPC Therapy, n ADT ADT+ABI ADT+non-ABI ARPI ADT+DOC Cohort Size 609 320 (53%) 118 (19%) 109 (18%) 62 (10%) Non-ABI APRI 226 (37%) 138 59 7 22 ABI 153 (25%) 103 - 37 13 Chemotherapy 136 (22%) 38 38 45 15 Immunotherapy 28 (5%) 15 3 6 4 Radiopharmaceuticals 19 (3%) 7 3 6 3 PARPi 13 (2%) 4 4 3 2 Combination Therapy 34 (6%) 15 11 5 3

Association of localized high-risk prostate cancer (PC) and an androgen receptor low subpopulation susceptible to HER2 inhibition.

Journal of Clinical Oncology Adam G. Sowalsky, Scott C. Wilkinson, Anson T. Ku et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.401

401 Background: Patients diagnosed with localized high-risk PC have higher rates of recurrence, and neoadjuvant intensive hormonal therapies seek to treat occult micrometastatic disease by addition to definitive treatment. We completed a phase 2 trial of neoadjuvant androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide (enza) for 6 months prior to radical prostatectomy (RP), in which 22 out of 37 patients exhibited poor pathologic responses (NCT02430480). In the current study, we aimed to identify targetable mechanisms of poor response evident in baseline biopsies that correlated with pathologic response. Methods: RNA-seq was performed on 147 laser microdissected foci from 99 biopsy blocks acquired prior to the initiation of neoadjuvant therapy. Pathologic response was measured directly from posttreatment RP H&amp;E slides. Differential expression was determined using linear mixed-effects models with histologic features and patients as random effects and residual cancer volume as a fixed effect. Differentially enriched pathways were identified using Ingenuity Pathway Analysis. Protein and phosphoprotein levels were measured in tissues using immunohistochemistry and analyzed using machine learning algorithms. Sensitivity and differential responses in cell lines and patient-derived organoids were measured using dose responsive curves, RNA-seq, single-cell sequencing and flow cytometry. Results: Gene signatures of higher AR activity were associated with exceptional responses (defined as less than 0.05 cm 3 of residual tumor in the RP), which was inversely associated with HER2 activity. High HER2 activity was associated with poorer outcomes. The inverse relationship between AR and HER2 activity was validated in three additional cohorts by RNA-seq and multiplex immunofluorescence. Tumors demonstrating resistance to ADT+enza expressed higher levels of HER2 and pHER2 protein at baseline. PC cell lines (including LNCaP and LAPC-4) treated with low doses of HER2 inhibitors (afatinib and neratinib) selected for populations with low AR activity as measured by RNA-seq, immunoblotting and flow cytometry. Combining enza+neratinib increased cell death, but patient-derived PC organoids exposed to 3-5 μM neratinib alone resulted in 90% cell death after 48h. Using single-cell sequencing and AR/HER2/PSA multiplex immunofluorescence, we found that most high-grade hormone-sensitive prostate tumors harbor a HER2-high subpopulation of cells with lower levels of AR activity that are resistant to AR inhibitors but sensitive to HER2 inhibition. Conclusions: Nascent human prostate tumors adopt an AR activity-low state prior to antiandrogen exposure that can be exploited by treatment with HER2 inhibitors, including novel combinations in the neoadjuvant or adjuvant setting. Future NCI clinical trials will evaluate such combinations. Clinical trial information: NCT02430480 .

Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer.

Journal of Clinical Oncology Catharina Op't Hoog, Niven Mehra, Anouk van Kleef et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.148

148 Background: Enzalutamide is a potent androgen receptor signal inhibitor used in the treatment of various stages of prostate cancer. However, treatment with enzalutamide is challenging due to its high potential for drug-drug interactions, particularly in the typically older population of prostate cancer patients with often comorbidities treated with multiple drugs. Anticoagulants are such a class of drugs often co-administered with enzalutamide. While low-molecular-weight heparin can be safely combined with enzalutamide, the safety of combining enzalutamide with more patient-friendly direct oral anticoagulants remains uncertain. The objective of this study was to assess whether a drug-drug interaction exists between enzalutamide and edoxaban. Methods: A prospective, multicenter, open-label, two-arm parallel study was performed in men with prostate cancer who are treated with edoxaban, with and without enzalutamide. Plasma concentrations of edoxaban were measured at steady state. Pharmacokinetic (PK) parameters were calculated using non-compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration time curve over one dosing interval (AUC 0-24h ) were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR was within the range of 0.8–1.25. Patients kept a patient diary to record medication intake and adverse events. Results: Sixteen patients with prostate cancer using edoxaban (eight patients with enzalutamide and eight patients without enzalutamide) were enrolled. Measured PK parameters are shown in the table. The exposure of edoxaban was similar when combined with enzalutamide, however the 90% CI fell outside of the 0.8-1.25 range (AUC 0–24h GMR 1.03; 90% CI 0.78 – 1.35). No adverse events were reported during the study. Conclusions: The average exposure of edoxaban was similar with and without enzalutamide. However, bioequivalence could not be established due to the broader than anticipated confidence interval. Despite this, the larger variability is not considered to have clinical consequences, supporting the safe co-administration of these drugs in clinical practice. Clinical trial information: NCT05339672 . Pharmacokinetic parameters edoxaban with and without enzalutamide (data are represented as geometric mean (CV%) [confidence interval]). Edoxaban + enzalutamide[90% CI] Edoxaban[90% CI] GMR [90% CI] Edoxaban AUC 0-24h (h*µg/L) 2034.72 (18%)[1711.71 – 2418.68] 1981.94 (47%)[1430.29 – 2746.36] 1.03[0.78 – 1.35] C max (µg/L) 304.30 (28%)[231.79 – 399.48] 254.91 (31%)[198.74 – 326.95] 1.19[0.91 – 1.57] C trough (µg/L) 18.93(37%)[14.12 – 25.37] 21.49 (97%)[11.00 – 41.98] 0.88[0.51 – 1.52] AUC 0-24h , area under the plasma concentration time-curve 0-24 hours; C max , maximum plasma concentration; C trough , trough plasma concentration; GMR, geometric mean ratio; CI, confidence interval; CV, coefficient of variation.